Merus (NASDAQ:MRUS) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Saturday, April 7th.
A number of other research analysts have also recently commented on MRUS. ValuEngine upgraded Merus from a “strong sell” rating to a “sell” rating in a research note on Monday, April 2nd. Wedbush restated an “outperform” rating and set a $32.00 price objective on shares of Merus in a research note on Friday, January 12th. Finally, Royal Bank of Canada cut Merus from an “outperform” rating to a “sector perform” rating and set a $28.00 price objective on the stock. in a research note on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $30.00.
Shares of MRUS opened at $17.68 on Friday. Merus has a 12 month low of $13.23 and a 12 month high of $23.75.
An institutional investor recently bought a new position in Merus stock. Bain Capital Public Equity Management LLC acquired a new position in shares of Merus (NASDAQ:MRUS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 196,090 shares of the biotechnology company’s stock, valued at approximately $8,297,000. Bain Capital Public Equity Management LLC owned approximately 1.01% of Merus at the end of the most recent reporting period. Institutional investors and hedge funds own 30.81% of the company’s stock.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers.
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.